Arsenic activates EGFR pathway signaling in the lung

Toxicological Sciences

Volumn 109, Issue 2, 2009, Pages 350-357

  Andrew, Angeline S ^a,b   Mason, Rebecca A ^a   Memoli, Vincent ^b   Duell, Eric J ^a,b,c  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Arsenic; Cyclin D1; Epidermal growth factor; Human; Lung cancer

Indexed keywords

ARSENIC; CYCLIN D1; CYCLOHEXIMIDE; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; EPITHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ALVEOLUS EPITHELIUM; LUNG CANCER; PHARMACOLOGICAL BLOCKING; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADULT; AGED; ANALYSIS OF VARIANCE; ARSENIC; ARSENITES; BIOLOGICAL MARKERS; BRONCHI; CELLS, CULTURED; CYCLIN D1; CYCLOHEXIMIDE; EPIDERMAL GROWTH FACTOR; EPITHELIAL CELLS; GENE EXPRESSION; GLYCOPROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG; LUNG NEOPLASMS; MIDDLE AGED; NAILS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SODIUM COMPOUNDS;

EID: 66149148676     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfp015     Document Type: Article

References (55)

1. Abernathy, C. O., Liu, Y. P., Longfellow, D., Aposhian, H. V., Beck, B., Fowler, B., Goyer, R., Menzer, R., Rossman, T., Thompson, C., et al. (1999). Arsenic: Health effects, mechanisms of actions, and research issues. Environ. Health Perspect. 107, 593-597.
2. ACS. (2007). Lung Cancer (Non-Small Cell), Vol. 2007. American Cancer Society, Atlanta, GA. Available from: www.cancer.org.
3. Andrew, A., and Barchowsky, A. (2000). Nickel-induced plasminogen activator inhibitor-1 expression inhibits the fibrinolytic activity of human airway epithelial cells. Toxicol. Appl. Pharmacol. 168 50-57.
4. Andrew, A. S., Klei, L. R., and Barchowsky, A. (2001a). AP-1-dependent induction of plasminogen activator inhibitor-1 by nickel does not require reactive oxygen. Am. J. Physiol. Lung Cell. Mol. Physiol. 281, L616-L623.
5. Andrew, A. S., Klei, L. R., and Barchowsky, A. (2001b). Nickel requires hypoxia-inducible factor-1 alpha, not redox signaling, to induce plasminogen activator inhibitor-1. Am. J. Physiol. Lung Cell. Mol. Physiol. 281, L607-L615.
6. ATSDR. (1999). Toxicological Profile for Arsenic. Agency for Toxic Substances and Disease Registry (ATSDR), Atlanta, GA.
7. Barchowsky, A., Soucy, N. V., O'Hara, K. A., Hwa, J., Noreault, T. L., and Andrew, A. S. (2002). Novel pathway for nickel-induced interleukin-8 expression. J Biol. Chem. 277, 24225-24231.
8. Celik, I., Gallicchio, L., Boyd, K., Lam, T. K., Matanoski, G., Tao, X., Shiels, M., Hammond, E., Chen, L., Robinson, K. A., et al. (2008). Arsenic in drinking water and lung cancer: A systematic review. Environ. Res. 108, 48-55.
9. Cheng, T., Morris, J., Koirtyohann, S., Spate, V., and Baskett, C. (1995). Study of the correlation of trace elements in carpenter's toenails. J. Radioanal. Cucl. Chem. 195, 31-42.
10. Clark, G. M., Zborowski, D. M., Santabarbara, P., Ding, K., Whitehead, M., Seymour, L., and Shepherd, F. A. (2006). Smoking history and epidermal growth factor receptor expression as predictors of survival benefit fromerlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Clin. Lung Cancer 7, 389-394.
11. Eblin, K. E., Bredfeldt, T. G., Buffington, S., and Gandolfi, A. J. (2007). Mitogenic signal transduction caused by monomethylarsonous acid in human bladder cells: Role in arsenic-induced carcinogenesis. Toxicol. Sci. 95, 321-30.
12. Fu, M., Wang, C., Li, Z., Sakamaki, T., and Pestell, R. G. (2004). Minireview: Cyclin D1: Normal and abnormal functions. Endocrinology 145, 5439-5447.
13. Gschwind, A., Fischer, O. M., and Ullrich, A. (2004). The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat. Rev. Cancer 4, 361-370.
14. Herbst, R. S., Fukuoka, M., and Baselga, J. (2004). Gefitinib - A novel targeted approach to treating cancer. Nat. Rev. Cancer 4, 956-965.
15. Hilbe, W., Dirnhofer, S., Oberwasserlechner, F., Eisterer, W., Ammann, K., Schmid, T., Hilbe, G., Thaler, J., and Woll, E. (2003). Immunohistochemical typing of non-small cell lung cancer on cryostat sections: Correlation with clinical parameters and prognosis. J. Clin. Pathol. 56, 736-41.
16. Huang, H. S., Liu, Z. M., Ding, L., Chang, W. C., Hsu, P. Y., Wang, S. H., Chi, C. C., and Chuang, C. H. (2006). Opposite effect of ERK1/2 and JNK on p53-independent p21(WAF1/CIP1) activation involved in the arsenic trioxide-induced human epidermoid carcinoma A431 cellular cytotoxicity. J. Biomed. Sci. 13, 113-125.
17. IARC. (2004). Some Drinking-Water Disinfectants and Contaminants, Including Arsenic. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, pp. 39-267. World Health Organization, International Agency for Research on Cancer Lyon, France.
18. Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., and Thun, M. J. (2004). Cancer statistics, 2004. CA Cancer J. Clin. 54, 8-29.
19. Karagas, M. R., Stukel, T. A., Morris, J. S., Tosteson, T. D., Weiss, J. E., Spencer, S. K., and Greenberg, E. R. (2001). Skin cancer risk in relation to toenail arsenic concentrations in a US population-based case-control study. Am. J. Epidemiol. 153, 559-565.
20. Karagas, M. R., Stukel, T. A., and Tosteson, T. D. (2002). Assessment of cancer risk and environmental levels of arsenic in New Hampshire. Int. J. Hyg. Environ. Health 205, 85-94.
21. Karagas, M. R., Tosteson, T. D., Blum, J., Klaue, B., Weiss, J. E., Stannard, V., Spate, V., and Morris, J. S. (2000). Measurement of low levels of arsenic exposure: A comparison of water and toenail concentrations. Am. J. Epidemiol. 152, 84-90.
22. Karagas, M. R., Tosteson, T. D., Morris, J. S., Demidenko, E., Mott, L. A., Heaney, J., and Schned, A. (2004). Incidence of Transitional Cell Carcinoma of the Bladder and Arsenic Exposure in New Hampshire. Cancer Causes Control 15, 465-472.
23. Kari, C., Chan, T. O., Rocha de Quadros, M., and Rodeck, U. (2003). Targeting the epidermal growth factor receptor in cancer: Apoptosis takes center stage. Cancer Res. 63, 1-5.
24. Li, Y., Chen, Y., Slavkovic, V., Ahsan, H., Parvez, F., Graziano, J. H., and Brandt-Rauf, P. W. (2007). Serum levels of the extracellular domain of the epidermal growth factor receptor in individuals exposed to arsenic in drinking water in Bangladesh. Biomarkers 12, 256-265.
25. Lin, Q., Yang, W., and Cerione, R. A. (2006). Measurement of epidermal growth factor receptor turnover and effects of Cdc42. Methods Enzymol. 406, 614-625.
26. Lin, S. Y., Makino, K., Xia, W., Matin, A., Wen, Y., Kwong, K. Y., Bourguignon, L., and Hung, M. C. (2001). Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol. 3, 802-808.
27. Liu, Z. M., and Huang, H. S. (2006). As(2)O(3)-induced c-Src/EGFR/ERK signaling is via Sp1 binding sites to stimulate p21(WAF1/CIP1) expression in human epidermoid carcinoma A431 cells. Cell Signal. 18, 244-255.
28. Moriuchi, A., Hirono, S., Ido, A., Ochiai, T., Nakama, T., Uto, H., Hori, T., Hayashi, K., and Tsubouchi, H. (2001). Additive and inhibitory effects of simultaneous treatment with growth factors on DNA synthesis through MAPK pathway and G1 cyclins in rat hepatocytes. Biochem. Biophys. Res. Commun. 280, 368-373.
29. Navarro Silvera, S. A., and Rohan, T. E. (2007). Trace elements and cancer risk: A review of the epidemiologic evidence. Cancer Causes Control 18, 7-27.
30. NRC. (2001). Arsenic in Drinking Water. National Academy Press, Washington, DC.
31. Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004). EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304, 1497-1500.
32. Pao, W., and Miller, V. A. (2005). Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions. J. Clin. Oncol. 23, 2556-2568.
33. Pedersen, M. W., Pedersen, N., Damstrup, L., Villingshoj, M., Sonder, S. U., Rieneck, K., Bovin, L. F., Spang-Thomsen, M., and Poulsen, H. S. (2005). Analysis of the epidermal growth factor receptor specific transcriptome: Effect of receptor expression level and an activating mutation. J. Cell Biochem. 96, 412-427.
34. Petty, W. J., Dragnev, K. H., and Dmitrovsky, E. (2003). Cyclin D1 as a target for chemoprevention. Lung Cancer 41(Suppl. 1), S155-S161.
35. Petty, W. J., Dragnev, K. H., Memoli, V. A., Ma, Y., Desai, N. B., Biddle, A., Davis, T. H., Nugent, W. C., Memoli, N., Hamilton, M., et al. (2004). Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. Clin. Cancer Res. 10, 7547-7554.
36. Pore, N., Jiang, Z., Gupta, A., Cerniglia, G., Kao, G. D., and Maity, A. (2006). EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res. 66, 3197-3204.
37. Reissmann, P. T., Koga, H., Figlin, R. A., Holmes, E. C., and Slamon, D. J. (1999). Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group. J. Cancer Res. Clin. Oncol. 125, 61-70.
38. Rossman, T. G. (2003). Mechanism of arsenic carcinogenesis: An integrated approach. Mutat. Res. 533, 37-65.
39. Rossman, T. G., Uddin, A. N., Burns, F. J., and Bosland, M. C. (2001). Arsenite is a cocarcinogen with solar ultraviolet radiation for mouse skin: An animal model for arsenic carcinogenesis. Toxicol. Appl. Pharmacol. 176, 64-71.
40. Sancar, A., Lindsey-Boltz, L. A., Unsal-Kaccmaz, K., and Linn, S. (2004). Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 73, 39-85.
41. Shen, F., Lin, Q., Gu, Y., Childress, C., and Yang, W. (2007). Activated Cdc42-associated kinase 1 is a component of EGF receptor signaling complex and regulates EGF receptor degradation. Mol. Biol. Cell 18, 732-742.
42. Simeonova, P. P., Wang, S., Hulderman, T., and Luster, M. I. (2002). c-Src-dependent activation of the epidermal growth factor receptor and mitogen-activated protein kinase pathway by arsenic. Role in carcinogenesis. J. Biol. Chem. 277, 2945-2950.
43. Smith, A. H., Marshall, G., Yuan, Y., Ferreccio, C., Liaw, J., von Ehrenstein, O., Steinmaus, C., Bates, M. N., and Selvin, S. (2006). Increased mortality from lung cancer and bronchiectasis in young adults after exposure to arsenic in utero and in early childhood. Environ. Health Perspect. 114, 1293-1296.
44. Smith, K. R., Klei, L. R., and Barchowsky, A. (2001). Arsenite stimulates plasma membrane NADPH oxidase in vascular endothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 280, L442-L449.
45. Souza, K., Maddock, D. A., Zhang, Q., Chen, J., Chiu, C., Mehta, S., and Wan, Y. (2001). Arsenite activation of P13K/AKT cell survival pathway is mediated by p38 in cultured human keratinocytes. Mol. Med. 7 767-772.
46. Steinmaus, C., Yuan, Y., Bates, M. N., and Smith, A. H. (2003). Case-control study of bladder cancer and drinking water arsenic in the western United States. Am. J. Epidemiol. 158, 1193-1201.
47. Suzuki, N., Naranmandura, H., Hirano, S., and Suzuki, K. T. (2008). Theoretical calculations and reaction analysis on the interaction of pentavalent thioarsenicals with biorelevant thiol compounds. Chem. Res. Toxicol. 21, 550-553.
48. Tanaka-Kagawa, T., Hanioka, N., Yoshida, H., Jinno, H., and Ando, M. (2003). Arsenite and arsenate activate extracellular signal-regulated kinases 1/2 by an epidermal growth factor receptor-mediated pathway in normal human keratinocytes. Br. J. Dermatol. 149, 1116-1127.
49. Tran, H. P., Prakash, A. S., Barnard, R., Chiswell, B., and Ng, J. C. (2002). Arsenic inhibits the repair of DNA damage induced by benzo(a)pyrene. Toxicol. Lett. 133, 59-67.
50. Travis, W. D., Brambilla, E., Muller-Hermelink, H. K., Harris, C. C., Eds. (2004). Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, France.
51. Vogt, B. L., and Rossman, T. G. (2001). Effects of arsenite on p53, p21 and cyclin D expression in normal human fibroblasts - A possible mechanism for arsenite's comutagenicity. Mutat. Res. 478, 159-168.
52. Wei, M., Wanibuchi, H., Morimura, K., Iwai, S., Yoshida, K., Endo, G., Nakae, D., and Fukushima, S. (2002). Carcinogenicity of dimethylarsinic acid in male F344 rats and genetic alterations in induced urinary bladder tumors. Carcinogenesis 23, 1387-1397.
53. Witkiewicz-Kucharczyk, A., and Bal, W. (2006). Damage of zinc fingers in DNA repair proteins, a novel molecular mechanism in carcinogenesis. Toxicol. Lett. 162, 29-42.
54. Wu, W., Graves, L. M., Jaspers, I., Devlin, R. B., Reed, W., and Samet, J. M. (1999). Activation of the EGF receptor signaling pathway in human airway epithelial cells exposed to metals. Am. J. Physiol. 277 L924-L931.
55. Zaridze, D., Maximovitch, D., Zemlyanaya, G., Aitakov, Z. N., and Boffetta, P. (1998). Exposure to environmental tobacco smoke and risk of lung cancer in non-smoking women from Moscow, Russia. Int. J. Cancer 75, 335-338.